Citation, DOI & article data
Gadoversetamide (also known as OptiMARKTM) is an extracellular intravenous contrast agent used in magnetic resonance imaging.
- linear, non-ionic molecule
- 100% renally excreted
- T1 relaxivity @ 1.5 T: 4.4-5.0
- concentration: 0.5 mmol/ml
- recommended dosage: 0.1 mmol/kg
As an extracellular contrast agent, gadoversetamide can be useful in a wide range of MRI applications, including (but not limited to): hepatic imaging, pelvic imaging, cardiac imaging, brain and spine imaging, and musculoskeletal imaging.
There is an association between the use of gadolinium-based contrast agents (GBCAs) in patients with kidney dysfunction and nephrogenic systemic fibrosis (NSF), a rare, but serious, condition. As a result, the use of three GBCAs; gadoversetamide (OptiMARK®), gadopentetate dimeglumine (Magnevist®) and gadodiamide (Omniscan®) are contraindicated in patients with AKI or with chronic, severe kidney disease 2.
- 1. Guglielmo FF, Mitchell DG, Gupta S. Gadolinium contrast agent selection and optimal use for body MR imaging. Radiol. Clin. North Am. 2014;52 (4): 637-56. doi:10.1016/j.rcl.2014.02.004 - Pubmed citation
- 2. FDA. Information for healthcare professionals: Gadolinium-based contrast agents for magnetic resonance imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). link: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-warnings-using-gadolinium-based-contrast-agents-patients-kidney